Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement

Florian Kronenberg, Samia Mora, Erik S.G. Stroes, Brian A. Ference, Benoit J. Arsenault, Lars Berglund, Marc R. Dweck, Marlys Koschinsky, Gilles Lambert, François Mach, Catherine J. McNeal, Patrick M. Moriarty, Pradeep Natarajan, Børge G. Nordestgaard, Klaus G. Parhofer, Salim S. Virani, Arnold Von Eckardstein, Gerald F. Watts, Jane K. Stock, Kausik K. RayLale S. Tokgözoǧlu, Alberico L. Catapano

Research output: Contribution to journalReview articlepeer-review

315 Citations (Scopus)

Abstract

This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance for testing and treating elevated Lp(a) levels, and considers its inclusion in global risk estimation. Epidemiologic and genetic studies involving hundreds of thousands of individuals strongly support a causal and continuous association between Lp(a) concentration and cardiovascular outcomes in different ethnicities; elevated Lp(a) is a risk factor even at very low levels of low-density lipoprotein cholesterol. High Lp(a) is associated with both microcalcification and macrocalcification of the aortic valve. Current findings do not support Lp(a) as a risk factor for venous thrombotic events and impaired fibrinolysis. Very low Lp(a) levels may associate with increased risk of diabetes mellitus meriting further study. Lp(a) has pro-inflammatory and pro-Atherosclerotic properties, which may partly relate to the oxidized phospholipids carried by Lp(a). This panel recommends testing Lp(a) concentration at least once in adults; cascade testing has potential value in familial hypercholesterolaemia, or with family or personal history of (very) high Lp(a) or premature ASCVD. Without specific Lp(a)-lowering therapies, early intensive risk factor management is recommended, targeted according to global cardiovascular risk and Lp(a) level. Lipoprotein apheresis is an option for very high Lp(a) with progressive cardiovascular disease despite optimal management of risk factors. In conclusion, this statement reinforces evidence for Lp(a) as a causal risk factor for cardiovascular outcomes. Trials of specific Lp(a)-lowering treatments are critical to confirm clinical benefit for cardiovascular disease and aortic valve stenosis.

Original languageEnglish
Pages (from-to)3925-3946
Number of pages22
JournalEuropean Heart Journal
Volume43
Issue number39
DOIs
Publication statusPublished - 14 Oct 2022
Externally publishedYes

Keywords

  • Aortic stenosis
  • Cardiovascular risk
  • Clinical guidance
  • Consensus
  • Lipoprotein(a)
  • Model of care
  • Testing
  • Treatment

Fingerprint

Dive into the research topics of 'Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement'. Together they form a unique fingerprint.

Cite this